Barry O'Leary, CEO, IDA

Barry O’LearyCEO IDA Ireland

October 31 2012

http://www.biopharmasummit.com/

Current Impact of FDI

IDA Portfolio Companies

€115 billion

250,000

Current Impact of FDI

Two thirds Business Expenditure on R&D

http://images.google.ie/imgres?imgurl=http://www.banking.org.za/tcts/img/Citilogo.JPG&imgrefurl=http://www.banking.org.za/tcts/tcts.aspx&usg=__07_m_7vbkLcyhVjm-9wm3ukuccE=&h=308&w=448&sz=17&hl=en&start=4&itbs=1&tbnid=GO0KcYWJT-jZ_M:&tbnh=87&tbnw=127&prev=/images%3Fq%3Dcitilogo%26hl%3Den%26gbv%3D2%26tbs%3Disch:1

http://images.google.ie/imgres?imgurl=http://i.bnet.com/blogs/pfizer_logo-small.jpg&imgrefurl=http://industry.bnet.com/pharma/10004925/pfizer-wont-share-wyeths-q3-numbers-layoff-announcements-due-this-week/&usg=__f4n6qnwLrFHIjon50PkNyr8Z5wI=&h=149&w=198&sz=5&hl=en&start=2&um=1&itbs=1&tbnid=j05KXuy_lVe9-M:&tbnh=78&tbnw=104&prev=/images%3Fq%3Dpfizer%2Blogo%26um%3D1%26hl%3Den%26tbs%3Disch:1

http://images.google.ie/imgres?imgurl=http://www.ece.gatech.edu/enrichment/ors/images/intel-logo.gif&imgrefurl=http://www.ece.gatech.edu/enrichment/ors/sponsors.html&usg=__nET8LsuYhz5xi2HtN_El4qbpA3o=&h=225&w=300&sz=6&hl=en&start=2&itbs=1&tbnid=zVps6FjtgcZ5mM:&tbnh=87&tbnw=116&prev=/images%3Fq%3DINTEL%2Blogo%26hl%3Den%26gbv%3D2%26tbs%3Disch:1

http://images.google.ie/imgres?imgurl=http://www-903.ibm.com/kr/pressroom/files/IBMLOGO.jpg&imgrefurl=http://www-903.ibm.com/kr/pressroom/photo/PhotoList.jsp%3Fseqno%3D25&usg=__qxJybOhm16LMOISCRMSSq-Zyhzs=&h=857&w=1640&sz=106&hl=en&start=1&itbs=1&tbnid=7z7Yvs6jMabJhM:&tbnh=78&tbnw=150&prev=/images%3Fq%3DIBMlogo%26hl%3Den%26gbv%3D2%26tbs%3Disch:1

IDA Business Focus

IDA focus across industry segmentsLeading MNCs

2nd Tier

Emerging Companies

http://www.stream.com/default.aspx

Some wins to-date: January – October 2012

http://www.munichre.com/en/homepage/default.aspx

http://consero.com/

http://www.keyedin.com/

http://www.yapstone.com/index.html

Ireland – Pharma / BioPharma Cluster

http://www.pfizer.com/main.html

Lifescience Shared Services

Expansion of Sligo Pharmaceutical

Plant

$110m / 175 Jobs

Key Recent Pharma/Biopharma Investments

Dun Laoghaire Facility in Dublin

$200m / 100 Jobs

Expansion of biotech campus in

Grange Castle, Dublin

$200m

Expansion of development and

manufacturing operations

$350m / 200 Jobs

Newbiopharmaceutical

facility in Cork

$420m / 200 Jobs

Galway & Dublin; Development,

Manufacturing and Supply Chain Management

$ 500m / 500 Jobs

European HQ Sales and Manufacturing

Base

120 jobs

Cork Manufacturing Plant

$50m / 100 jobs

Bioassay Centre of Expertise

/Pneumococcal Vaccine Conjugation

Facility€29m

Initiatives to support Pharma / Biopharma Cluster Solid State Pharma Cluster

Pharmaceutical Manufacturing Technology Centre

National Institute for Bioprocessing Research and Training (NIBRT)

ACADEMIA INDUSTRY

What attracts FDI to Ireland?• Talent, Technology, Track Record (operational excellence), Tax, • Ease of doing Business , EU Access, English speaking are building blocks…• Sector / Activity / Country Specific• Ireland’s Value Proposition - Needs Constant Enhancement

Example – Biopharmaceuticals;- FDA Track Record- National Institute for Bioprocessing and Research Training (NIBRT)- Science Foundation Ireland Initiatives- Strategic Sites- Cluster Impact- Financial Incentives- Regulatory Environment

TEAM IRELAND

World Competitiveness RankingsIBM PLI Global Location Trends Report 2011; 2nd ranked destination by jobs per 100,000 inhabitants 1st ranked destination by value* of Investment projects

* a combination of Productivity, value-added, knowledge intensity and occupational profile composition

IMD World Competiveness Yearbook 2012 1st in the world for ready availability of skilled labour 1st for flexibility and adaptability of people to challenges 1st for investment incentives to attract foreign investors 2nd for positive attitudes towards globalization 2nd for adaptability of companies to market changes 3rd for unit labour costs in the manufacturing sector 3rd in the world for labour productivity 4th for corporate tax rate on profit

Up 4 Places to Number 20

FDI Outlook• Good immediate pipeline in Technology (ICT) Sector, Lifesciences, Financial Services,

Digital media / Content, Professional / International Services

• Flat European Market – Importance for FDI

– Global Outlook

• IDA needs to have more than 100+ investments in play at any one time

• Pipeline generation and conversion is a key focus

Thank You

Barry O'Leary, CEO, IDA

Health & Medicine

Transcript of Barry O'Leary, CEO, IDA